Neurotechnology

Science Corporation

A medical technology company developing retinal prostheses, biohybrid neural interfaces and research hardware.

At a glance

About $490M

Company-reported capital invested since founding, announced March 5, 2026. The recorded round below is part of this total.

Origins & connections

Co-founded by former Neuralink team members in 2021. Its PRIMA retinal implant reached a European commercial launch in July 2026.

Sources 4